Estrogens reduce the expression of YKL-40 in the retina: implications for eye and joint diseases

Jean-Marie Rakic1, Vincent Lambert, Manuel Deprez

  • 1Department of Ophthalmology, University Hospital, Sart-Tilman, Liège, Belgium. jmrakic@chu.ulg.ac.be

Abstract

Insights

Estradiol therapy downregulates YKL-40 gene expression in the eye. This finding is relevant to age-related macular degeneration (AMD) and hormonal replacement therapy effects.

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Genetics

Background:

  • Ovariectomy (OVX) in mice mimics menopause, affecting ocular tissues.
  • Estrogen levels influence various physiological processes, including those in the eye.
  • Age-related macular degeneration (AMD) is a leading cause of vision loss.

Purpose of the Study:

  • To investigate gene expression changes in the posterior eye segment of OVX mice.
  • To determine the effect of estradiol therapy on gene expression.
  • To identify genes relevant to age-related macular degeneration (AMD) pathogenesis.

Main Methods:

  • Gene expression profiling using cDNA array technology in OVX mice.
  • Validation of gene expression using RT-PCR.
  • Investigation of YKL-40 in human retinas and a murine model of choroidal neovascularization (CNV).

Main Results:

  • YKL-40 gene expression was significantly downregulated by 17-beta-estradiol in OVX mice.
  • YKL-40 was detected in human neural retina and retinal pigment epithelium (RPE).
  • YKL-40 expression was upregulated in experimental CNV and exudative AMD neovascular membranes.

Conclusions:

  • Retinal YKL-40 expression is modulated by serum estradiol levels.
  • YKL-40 may play a role in the development of AMD.
  • YKL-40 is a potential mediator in the context of hormonal replacement therapy.